Longevity Biotech is developing a new class of therapeutic candidates called Hybridtides™. The unique Hybridtide™ scaffold provides critical enhancements over traditional peptide development efforts (e.g. PEG, Lactam Bridges, aka ‘Staples’) as well as macrocycles, D-peptides and peptoids.
By leveraging non-natural amino acids, Longevity Biotech has unprecedented control over both molecular conformation and structure-based design elements. Hybridtides™ offer a unique peptidomimetic scaffold that both metabolically stable and structural stable. In addition to improving the stability of these peptides, product profile advantages include robust target selectivity, low immunogenicity, and the potential for signal bias.
